Skip to main content
Premium Trial:

Request an Annual Quote

Recent RNAi-Related Deals with Big Pharma

Premium
In the roughly seven years since Science declared RNA interference as its breakthrough of the year, the biopharmaceutical industry has warmed up significantly to the therapeutic potential of the gene-silencing technology. Most recently, GlaxoSmithKline struck a deal to collaborate with Regulus Therapeutics to develop microRNA-targeting drugs.
Click here for an overview of the biggest tie-ups between RNAi and microRA drug developers and big pharma/biotech.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.